2018
DOI: 10.1016/bs.apha.2018.04.003
|View full text |Cite
|
Sign up to set email alerts
|

Implementation of Pharmacogenomics in Everyday Clinical Settings

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
27
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 37 publications
(31 citation statements)
references
References 79 publications
0
27
0
Order By: Relevance
“…Despite overcoming these barriers and the initiation of numerous implementation programs [18,19], PGx is still not widely implemented in primary care. Remaining barriers outlined in the literature include a lack of evidence supporting clinical utility, undetermined timing and methodology of testing, a lack of HCPs' confidence to apply it in practice, patients' concern for privacy issues and a lack of reimbursement [20][21][22][23]. Furthermore, remaining barriers may differ when delivered in a single-gene reactive approach or a pre-emptive panel approach.…”
Section: Introductionmentioning
confidence: 99%
“…Despite overcoming these barriers and the initiation of numerous implementation programs [18,19], PGx is still not widely implemented in primary care. Remaining barriers outlined in the literature include a lack of evidence supporting clinical utility, undetermined timing and methodology of testing, a lack of HCPs' confidence to apply it in practice, patients' concern for privacy issues and a lack of reimbursement [20][21][22][23]. Furthermore, remaining barriers may differ when delivered in a single-gene reactive approach or a pre-emptive panel approach.…”
Section: Introductionmentioning
confidence: 99%
“…Querying clinically actionable variations using pharmacogenetic tests may allow for tailored drug treatments for each patient. Drug choice can be guided by those predicted to be most effective or the best tolerated based on the patient's unique genetic features [1,2]. Pharmacogenetic-guided treatment can also contribute to reduced health costs [3,4].…”
mentioning
confidence: 99%
“…4 b). Previous reports also highlighted the high SNV density and excess of rare nsSNVs of the CYP450 pathway [ 68 , 69 ] with 90–95% individuals carrying at least one actionable variant in CYP450 genes [ 70 ]. Another report predicted that ~ 32% (1949/6165) of SNVs at the CYP450 loci are putatively functional with CYP4F12 carrying amongst the most novel putatively functional variants [ 71 ] which is consistent with our observations that CYP4F12 is enriched with the highest number of pfSNVs (Additional file 1 : Table S9).…”
Section: Discussionmentioning
confidence: 99%